A high-profile Phase 3 failure for AstraZeneca and Ionis Pharmaceuticals’ Wainua (eplontersen) undercut expectations at ESC26 for the “heart disease gene silencer” strategy. The reporting indicates trial assumptions were complicated by patients also taking a Pfizer drug targeting the same condition. The outcome reinforces how overlapping background therapies can affect event rates and endpoint interpretation in cardiovascular RNA-silencing programs, adding uncertainty for developers building similar mechanistic approaches.